Segment information and revenue from contracts with customers - Information by operating segments (Details) € in Thousands	12 Months Ended
Dec. 31, 2023 EUR (€) segment	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Segment information
Number of reportable segments \| segment	2
Total Revenues from contracts with external customers	€ 48,536	€ 47,473	€ 42,234
Selling expense	12,564	9,924	9,326
Adjusted EBITDA	(19,120)	(27,857)	(38,124)
Depreciation and amortization (including impairments)	7,610	8,932	10,464
Research and development expenses	12,361	17,488	19,297
Share of income (loss) of investments accounted for by the equity method	(302)
Additions to property, plant and equipment and right-of-use assets	1,894	3,379	1,887
Additions to intangible assets	2,239	1,727	2,787
Other segment information
Research and development expenses	12,361	17,488	19,297
Pharmaceutical
Segment information
Total Revenues from contracts with external customers	14,802	16,115	15,641
Diagnostics
Segment information
Total Revenues from contracts with external customers	33,734	31,358	26,593
Operating segment
Segment information
Adjusted EBITDA EX	(19,120)	(27,857)	(38,124)
Operating segment \| Pharmaceutical
Segment information
Total Revenues from contracts with external customers	14,802	16,115	15,641
Adjusted EBITDA	1,589	6,802	4,785
Depreciation and amortization (including impairments)	877	801	2,076
Additions to property, plant and equipment and right-of-use assets	18	1,244	690
Additions to intangible assets	182	162	2,401
Operating segment \| Diagnostics
Segment information
Total Revenues from contracts with external customers	33,734	31,358	26,593
Adjusted EBITDA	5,087	6,438	3,030
Depreciation and amortization (including impairments)	1,338	1,790	2,539
Additions to property, plant and equipment and right-of-use assets	12	910	261
Additions to intangible assets		14
Operating segment \| JV
Segment information
Adjusted EBITDA	4,462
Share of income (loss) of investments accounted for by the equity method	(302)
Corporate
Segment information
Adjusted EBITDA	(30,258)	(41,097)	(45,939)
Depreciation and amortization (including impairments)	5,395	6,340	5,849
Research and development expenses	12,361	17,488	19,297
Additions to property, plant and equipment and right-of-use assets	1,864	1,225	936
Additions to intangible assets	€ 2,057	€ 1,551	€ 386

Amount of additions to property, plant and equipment and right-of use assets for continuing operations.

No definition available.

Name:	cntg_AdditionsToPropertyPlantAndEquipmentAndRightOfUseAssetsContinuingOperations
Namespace Prefix:	cntg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of operating income (loss) before adjusting corporate expenses, depreciation and amortization as well as share based payment expenses.

+ References

No definition available.

+ Details

Name:	cntg_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
Namespace Prefix:	cntg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of operating income (loss) before adjusting depreciation and amortization as well as share based payment expenses but after adjusting corporate expenses, attributable to reportable segment.

+ References

No definition available.

+ Details

Name:	cntg_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortizationAfterCorporateExpensesAttributableToReportableSegment
Namespace Prefix:	cntg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

No definition available.

+ Details

Name:	cntg_IfrsNumberOfReportableSegments
Namespace Prefix:	cntg_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	cntg_OtherSegmentInformationAbstract
Namespace Prefix:	cntg_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of expenditure directly attributable to research or development activities related to corporate and, recognized in profit or loss.

+ References

No definition available.

+ Details

Name:	cntg_ResearchAndDevelopmentExpenseCorporate
Namespace Prefix:	cntg_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The entity's share of the Income (loss) of investments accounted for using the equity method.

+ References

No definition available.

+ Details

Name:	cntg_ShareOfIncomeLossOfInvestmentsAccountedForByEquityMethod
Namespace Prefix:	cntg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2023-01-01
-Paragraph 118
-Subparagraph e
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of depreciation expense, amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss. [Refer: Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2023-01-01
-Paragraph 126
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ResearchAndDevelopmentExpense
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2023-01-01
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2023-01-01
-Paragraph 113
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of expense relating to selling activities of the entity.

+ References

+ Details

Name:	ifrs-full_SellingExpense
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	ifrs-full_SegmentsAxis=cntg_PharmaceuticalSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_SegmentsAxis=cntg_DiagnosticsSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_SegmentsAxis=cntg_J.v.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_SegmentConsolidationItemsAxis=cntg_IfrsCorporateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: